GLPwatch
Papers (10376)
Page 71 of 173, ranked by citation count.
- Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.
- Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.
- Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
- Glucagon-like peptide receptor agonists and risk for depression.
- GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair.
- Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
- Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
- The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
- Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
- Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
- Exendin-4 regulates redox homeostasis in rats fed with high-fat diet.
- Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
- Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.
- Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
- Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
- Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
- Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
- The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy.
- Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
- Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
- Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI).
- The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.
- GLP-1 receptor agonists today.
- Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
- Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats.
- Shielding effect of a PEG molecule of a mono-PEGylated peptide varies with PEG chain length.
- Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
- GLP-1 receptor agonist-induced polyarthritis: a case report.
- Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.
- Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
- GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.
- Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways.
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
- Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method.
- Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
- A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
- Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
- Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
- Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.
- The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.
- Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease.
- Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
- Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.
- Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy-Is Exendin-4 the Answer?
- Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.
- C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
- A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.
- Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
- Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.
- A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction.
- Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.
- Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?
- Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.
- Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
- Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese mice.
- Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
- Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
- Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice.
- Efficacy of semaglutide versus liraglutide in clinical practice.
- Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.